To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous
nystatin in patients with HIV infection who have completed protocol FDA 103C. To evaluate
the safety and potential antiviral activity of intravenous nystatin and oral didanosine
(ddI) administered in an alternating regimen in this patient population.
Patients who have completed protocol FDA 103B are offered the option of receiving extended
maintenance. Patients who have received no prior ddI are treated either with intravenous
nystatin alone (at the same dose level administered in FDA 103B) or with a regimen of
intravenous nystatin and ddI alternating on 3-week cycles. Treatment continues for 12 weeks.
Patients must have:
- Completed 12 weeks of therapy with intravenous nystatin on protocol FDA 103B.
- No evidence of toxicity or progression of disease on protocol FDA 103B. (See protocol
FDA 103B for initial entry requirements.)
Active drug or alcohol abuse.